

HOMBURGER ADVISED BIOVERSYS ON THE EXTENSION OF ITS SERIES C FUNDRAISING ROUND

Posted on 11 January 2023



Categories: [Banking & Finance](#), [Corporate](#)

Tags: [BioVersys](#), [Dieter Gericke](#), [Homburger](#), [Slider](#), [Thierry Burkhardt](#)



On January 5, 2023, **BioVersys** announced that the **AMR Action Fund** has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based investment of the AMR Action Fund. The funds will go towards further trials of the pharmaceutical company's assets.

BioVersys is a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is a Venture Kick winner as well as a Venture Leaders alum. It ranked among the TOP 100 Swiss Startups from 2011 to 2013.

[Homburger](#) has advised **BioVersys** in this transaction. The legal team comprised partner **Dieter Gericke** (pictured left) and associate **Thierry Burckhardt** (pictured right; both Corporate / M&A).